Company intelligence / Profile preview

ART-mRNA

Ownership: Private
Development stage: Other

Overview

ART BioScience is a private Israeli biotechnology company developing mRNA-based genetic medicines for rare diseases, with a primary focus on Duchenne muscular dystrophy. The company was founded by Oren Ozeri and Alon Hazan and is building therapies based on modified dystrophin mRNA delivered through a proprietary lipid nanoparticle system designed for systemic muscle delivery. ART BioScience also describes a CRISPR-Cas9 mRNA gene-editing approach as part of its broader technology base. The company presents itself as a platform biotech centered on mRNA therapeutics and delivery technologies for genetic musculoskeletal disorders. Its disclosed pipeline appears to remain in the discovery to preclinical stage.

Therapeutic areas: Rare Diseases
Modalities: mRNA-based drugsBiologicGene therapyLipid nanoparticle delivery therapyCRISPR-based therapy
Industry: Biotech

Drug pipeline

1 asset

ART-030

Preclinical

Partnerships

Lipid technology licensed from the laboratory of Professor Dan Peer

Beyond the preview

Go deeper on ART-mRNA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART-mRNA.

Explore the full profile